Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma Clinical Trial

Official title:

Phase I, Multicenter, Open Label, Dose Escalation Of 90Y-Zevalin Radioimmunotherapy Using A Modified Treatment Regimen For Relapsed Or Refractory CD20+ B-Cell (Follicular/Transformed) Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00033423
• Other study ID #: CDR0000069282
• Secondary ID: UAB-0127UAB-F010
• Status: Terminated
• Phase: Phase 1
• First received: April 9, 2002
• Last updated: December 12, 2013
• Start date: August 2001
• Est. completion date: May 2009

Study information

• Verified date: December 2013
• Source: University of Alabama at Birmingham
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.

Description:

OBJECTIVES:

• Determine the maximum tolerated dose of yttrium Y 90 ibritumomab tiuxetan when administered in combination with rituximab in patients with relapsed or refractory low-grade, follicular, or transformed CD20-positive B-cell non-Hodgkin's lymphoma (NHL).

• Determine the toxicity of different doses of yttrium Y 90 ibritumomab tiuxetan in patients treated with this regimen.

• Determine the frequency of reversal of bone marrow involvement with NHL in patients treated with this regimen.

• Determine the antitumor response in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of yttrium Y 90 ibritumomab tiuxetan.

Patients receive rituximab IV once weekly on weeks 1-4. After 4 doses of rituximab, patients without bone marrow involvement and cellularity greater than 50% expected receive rituximab IV once weekly on weeks 6 and 7 and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes with the final dose of rituximab (day 43).

Cohorts of 5-6 patients receive escalating dose of yttrium Y 90 ibritumomab tiuxetan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 4 of 5 or 3 of 6 patients experience dose-limiting toxicity.

Patients are followed at 6 and 12 weeks, every 2-3 months for 2 years, and then every 6 months for 2 years.

PROJECTED ACCRUAL: Approximately 6-30 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: May 2009
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed low-grade, follicular, or transformed CD20-positive B-cell non-Hodgkin's lymphoma (NHL)

• Relapsed after prior chemotherapy OR chemotherapy-resistant disease

• Failed at least 1 prior chemotherapy regimen

• CD20-positive B-cell population in lymph nodes or bone marrow for International Working Formulation A (small lymphocytic lymphoma) and transformed NHL

• Bone marrow involvement with lymphoma less than 25% bilaterally

• No impaired bone marrow reserve defined as at least 1 of the following criteria:

• Prior myeloablative therapies with bone marrow transplantation or peripheral blood stem cell rescue

• Platelet count less than 100,000/mm3

• Bone marrow cellularity no greater than 15%

• Marked reduction in bone marrow precursors of one or more cell lines (e.g., granulocytic, megakaryocytic, or erythroid)

• Failed prior stem cell collection

• No CNS lymphoma, chronic lymphocytic lymphoma, or HIV or AIDS-related lymphoma

• No diffuse small lymphocytic/marginal zone lymphoma with lymphocyte count greater than 5,000/mm^3

• No pleural effusion NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age:

• 19 and over

Performance status:

• WHO 0-2

Life expectancy:

• At least 6 months

Hematopoietic:

• See Disease Characteristics

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Hematocrit greater than 30%

• Hemoglobin greater than 9.0 g/dL

Hepatic:

• Bilirubin no greater than 1.5 mg/dL

Renal:

• Creatinine no greater than 1.5 mg/dL

Other:

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 6 months after study participation

• No anti-murine antibody reactivity if prior exposure to murine antibodies or proteins

• No other primary malignancy

• No other serious nonmalignant disease or infection that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

• No prior radioimmunotherapy

• Prior rituximab allowed if more than 6 months to progression after an objective response

• At least 6 weeks since prior rituximab

• At least 3 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)

• Recovered from prior immunotherapy

Chemotherapy:

• See Disease Characteristics

• No prior fludarabine

• At least 3 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

• No concurrent chemotherapy

Endocrine therapy:

• At least 3 weeks since prior anticancer endocrine therapy

• No concurrent high-dose systemic corticosteroids (e.g., 50 mg or more of prednisone as a single dose or 50 mg or less of prednisone for more than 6 doses)

Radiotherapy:

• No prior radiotherapy to more than 25% of active bone marrow (involved field or regional)

• At least 3 weeks since prior anticancer radiotherapy and recovered

Surgery:

• At least 4 weeks since prior surgery (except diagnostic surgery) and recovered

Other:

• No other concurrent anticancer therapy

• Concurrent oral anticoagulant therapy allowed if platelet count is at least 30,000/mm3

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin

Intervention

Biological:
• rituximab

Radiation:
• yttrium Y 90 ibritumomab tiuxetan

Locations

Country	Name	City	State
United States	Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham	Birmingham	Alabama
United States	Mayo Clinic Cancer Center	Rochester	Minnesota
United States	Stanford Comprehensive Cancer Center - Stanford	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
University of Alabama at Birmingham	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Forero-Torres A, Besh S, Knox S, et al.: Higher doses of Rituxan alter pharmacokinetics and biodistribution of Zevalin but may increase responses; a preliminary report of a phase I study of Zevalin using a modified treatment regimen for relapsed or refrac

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the maximum tolerated dose of yttrium Y 90 ibritumomab tiuxetan when administered in combination with rituximab in patients with relapsed or refractory low-grade, follicular, or transformed CD20-positive B-cell non-Hodgkin's lymphoma (NHL).		baseline through 4 years	Yes
Secondary	Determine the toxicity of different doses of yttrium Y 90 ibritumomab tiuxetan in patients treated with this regimen		baseline through 4 years	Yes
Secondary	Determine the frequency of reversal of bone marrow involvement with NHL in patients treated with this regimen.		baseline through 4 years	No
Secondary	Determine the antitumor response in patients treated with this regimen.		baseline through 4 years	No